NASDAQ: RYZB - RayzeBio, Inc. Common Stock

Rentabilité sur six mois: 0%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions RayzeBio, Inc. Common Stock

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise RayzeBio, Inc. Common Stock

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).

plus de détails
It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2023-09-14
ISIN US75525N1072
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://rayzebio.com
Цена ао 62.49
Changement de prix par jour: 0% (62.49)
Changement de prix par semaine: 0% (62.49)
Changement de prix par mois: 0% (62.49)
Changement de prix sur 3 mois: 0% (62.49)
Changement de prix sur six mois: 0% (62.49)
Changement de prix par an: 0% (62.49)
Evolution des prix depuis le début de l'année: 0% (62.49)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 953.57 10
Rentabilité EPS, % 2126.11 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Viking Global Investors, L.P. 6642700 11.09
venBio Partners LLC 5158162 8.61
Versant Venture Management, LLC 5158161 8.61
VR Adviser, LLC 4030471 6.73
Wellington Management Group, LLP 3504409 5.85
Sofinnova Investments, Inc. 2419528 4.04
Orbimed Advisors LLC. 2365213 3.95
Redmile Group, LLC 1857706 3.1
Samsara BioCapital, LLC 1845948 3.08
Blackrock Inc. 1368838 2.28



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Kenneth Song M.D. President, CEO & Director 646k 1975 (50 années)
Mr. Arvind Kush Chief Financial Officer 714.76k 1983 (42 année)
Dr. Susan Moran M.D. Chief Medical Officer 559.84k 1969 (56 années)
Mr. Aron Marc Knickerbocker Co-Founder N/A 1969 (56 années)
Mr. Jeff Woodley General Counsel N/A
Mr. Eric Bischoff Senior Vice President of Development & Operations N/A
Dr. Gary G. Li Ph.D. Senior Vice President of Biology & Translational Medicine N/A
Ms. Kimberly Ma M.S. Senior Vice President of Clinical Operations N/A
Dr. Nicholas D. Smith Ph.D. Senior Vice President of Chemistry Innovation N/A
Mr. Abhi Bhat Ph.D. Senior VP of Chemistry & Head of Discovery N/A

Adresse: United States, San Diego. CA, 5505 Morehouse Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://rayzebio.com